Empagliflozin

empagliflozin

SGLT2 inhibitor. In a 12-month pilot RCT in 50 adults with high-risk ADPKD (J Am Soc Nephrol, 24 October 2026; PMID 42925875), it was well tolerated, but height-adjusted total kidney volume grew 10.5%/yr vs 5.1%/yr on placebo; no difference in chronic eGFR slope. Not established for ADPKD.